Aug. 22, 2011
/PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in
, today announced the release of an in-depth research report update by
, CFA, principal of fee-based, third-party research firm Murphy Analytics.
In his report, Mr. Murphy discusses Tibet Pharmaceuticals' business and current portfolio of five traditional Tibetan medicine products, outlines recent developments and states that Tibet is trading at less than cash value.
"Through our strong growth initiatives and portfolio of five SFDA-approved medicines, Tibet Pharmaceuticals is addressing the increasing demand for pharmaceutical and healthcare products in
, CEO and Chairman of Tibet Pharmaceuticals. "This research report update provides investors with an in-depth analysis of Tibet's particular strengths in the Traditional Chinese Medicine, or TCM, market in
and delivers a comprehensive overview of our recently reported revenue and earnings as we seek to continue to drive growth in 2011."
This research report update provides investors with a current analysis of the growth of the Chinese pharmaceutical market, and delivers a comprehensive overview of Tibet Pharmaceuticals' recently-reported revenue and earnings. Murphy Analytics also explains that despite Tibet Pharmaceuticals' revenue growth, its current valuation multiple is lower than many of its peers.
In his updated report, Mr. Murphy states, "Various benchmark indices, with varying degrees of relevance for TBET operations, are trading at price / earnings multiples ranging from 12.6x to 20.5x. A smaller sampling of publicly traded stocks generally operating in the Chinese healthcare / pharmaceutical sector is trading at an average P/E multiple of 5.3x, while TBET is trading at less than half the multiple for this sampling and generally in line with peers that are struggling rather than reporting earnings and revenue growth like TBET."